Previous 10 | Next 10 |
Phathom Pharmaceuticals ( NASDAQ: PHAT ) plunged 25% in after-hours trading on Tuesday after it was informed by the US FDA that the agency would not render a decision on its vonoprazan NDA for erosive esophagitis by the Jan. 11 PDUFA date . In early August 2022, the compa...
FLORHAM PARK, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced that the U.S. Food and Drug Administration (FDA) ...
Summary PHAT, a Takeda spinoff, has a drug approved in H. pylori. The same drug has a PDUFA in a GERD subtype. The company is somewhat unexciting, being in a low-value market, however, it has some growth potential. Phathom Pharmaceuticals, Inc. ( PHAT ) develops ...
Patient enrollment completed for Phase 3 non-erosive gastroesophageal reflux disease (NERD) daily dosing trial with topline data for primary endpoint expected in Q1 2023 Obtained commitment for up to an additional $40 million under revenue interest financing agreement; total financi...
FLORHAM PARK, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today that members of its management team will pa...
Up to $40 million committed, resulting in total financing of up to $300 million available to Phathom with total royalty payments capped at 2.0x invested capital Provides agreement for additional $15 million upon FDA approval of vonoprazan for treatment of erosive esophagitis (EE) ...
A total of 776 patients with symptomatic NERD have been enrolled and randomized in the multisite trial across the U.S. Topline data for the primary endpoint is expected in Q1 2023 with full trial results available in late-2023 NERD is the largest subcategory of gastroesoph...
FLORHAM PARK, N.J., Oct. 23, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today that detailed results from an investigation...
FLORHAM PARK, N.J., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today the company will present new data and resea...
FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced the appointment of James “Jamie...
News, Short Squeeze, Breakout and More Instantly...
Phathom Pharmaceuticals Inc. Company Name:
PHAT Stock Symbol:
NYSE Market:
Phathom Pharmaceuticals Inc. Website:
2024-06-23 22:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...